Top Page
Inmune Bio
(NASDAQ:INMB)
Inmune Bio (INMB) vs. SPDR S&P 500 ETF (SPY)
Inmune Bio Business Overview & Revenue Model
Inmune Bio Earnings Call Summary
Inmune Bio Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K | 11.00K |
| Gross Profit | 22.00K | 14.00K | 155.00K | 374.00K | 181.00K | 11.00K |
| EBITDA | -33.62M | -42.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -49.89M | -42.08M | -30.01M | -27.30M | -30.34M | -12.10M |
Balance Sheet | ||||||
| Total Assets | 33.36M | 39.56M | 57.00M | 81.80M | 99.94M | 40.66M |
| Cash, Cash Equivalents and Short-Term Investments | 27.73M | 20.92M | 35.85M | 52.15M | 74.81M | 21.97M |
| Total Debt | 1.08M | 384.00K | 10.44M | 15.31M | 15.23M | 160.00K |
| Total Liabilities | 7.98M | 7.46M | 18.86M | 21.69M | 19.72M | 1.90M |
| Stockholders Equity | 25.38M | 32.10M | 38.14M | 60.10M | 80.22M | 38.75M |
Cash Flow | ||||||
| Free Cash Flow | -31.55M | -33.36M | -11.98M | -22.69M | -43.50M | -8.94M |
| Operating Cash Flow | -30.65M | -33.36M | -11.98M | -22.69M | -28.50M | -8.94M |
| Investing Cash Flow | -899.00K | 0.00 | 0.00 | 0.00 | -15.00M | 0.00 |
| Financing Cash Flow | 25.47M | 18.21M | -4.22M | 729.00K | 96.36M | 23.90M |
Inmune Bio Technical Analysis
Inmune Bio Risk Analysis
Inmune Bio Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $131.65M | -0.46 | ― | ― | -3.98% | -29.94% | |
46 Neutral | $40.94M | -0.76 | -155.77% | ― | 19.05% | 2.01% | |
45 Neutral | $37.56M | -1.90 | -61.92% | ― | -100.00% | 55.10% | |
44 Neutral | $38.35M | -0.39 | ― | ― | -15.81% | -113.06% | |
42 Neutral | $31.11M | -0.61 | -195.19% | ― | -25.51% | 49.72% |
Inmune Bio Corporate Events
On December 22, 2025, INmune Bio Inc. amended certain investor warrants issued in its April 24 and April 29, 2024 offerings, adjusting the terms on 1,348,315 outstanding warrants. The company reduced the exercise price of these April 2024 warrants to $1.95, a level above Nasdaq’s defined minimum price as of December 17, 2025, and extended their expiration date to June 30, 2026, in exchange for a $0.05 per warrant payment, generating $67,416 in proceeds and potentially improving the warrants’ attractiveness to holders while modestly strengthening the company’s near-term funding flexibility.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
On December 19, 2025, INmune Bio Inc. entered into a sales agreement with A.G.P./Alliance Global Partners, allowing the company to sell up to $65 million of its common stock from time to time through at-the-market offerings under an existing shelf registration. The company is not obligated to issue any shares, but A.G.P. will act as sales agent subject to customary conditions, earning a 3% commission on gross proceeds and receiving indemnification, contribution rights, and expense reimbursements, providing INmune Bio with flexible access to additional capital that could support its operational and development needs while potentially diluting existing shareholders over time.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
INmune Bio Inc. announced the termination of its Amended and Restated At-The-Market Sales Agreement with RBC Capital Markets, LLC and BTIG, LLC, effective December 19, 2025. The company had previously raised approximately $10.5 million through the sale of 1,353,469 shares of common stock under this agreement, and the termination incurs no penalties or additional expenses.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
On December 1, 2025, INmune Bio Inc. announced new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595, presented at the Clinical Trials on Alzheimer’s Disease conference. The data, which showed a trend towards slowed neurodegeneration in patients with early Alzheimer’s disease and high inflammatory burden, reinforce XPro1595’s potential as a promising therapy for inflammation-driven Alzheimer’s, a large unmet market need.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
On December 2, 2025, INmune Bio Inc. announced amendments to the employment agreements of its President and Chief Executive, David J. Moss, and its Chief Financial Officer, Cory Ellspermann. The amendments corrected errors in the original agreements dated November 26, 2025, adjusting Moss’s base salary to $454,000 per annum and his stock option grant to 750,000 shares, while Ellspermann’s base salary was restated to $240,000 per annum.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
On November 26, 2025, INmune Bio Inc. announced new employment agreements for key executives, effective November 1, 2025. David J. Moss, President and CEO, will receive a base salary of $500,000, a discretionary bonus, and stock options, with provisions for change of control and involuntary termination. Cory Ellspermann, CFO, will have a base salary of $275,000, a discretionary bonus, and stock options, with similar provisions. Mark Lowdell, Chief Scientific Officer, under the subsidiary INmune Bio International Limited, will receive a salary of £300,000, a discretionary bonus, and benefits, with terms for termination and severance. These agreements aim to secure leadership stability and align executive incentives with company performance.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
On November 18, 2025, INmune Bio held a virtual special meeting of stockholders where the Option Repricing Proposal was approved. The company also announced its participation in the 18th Clinical Trials on Alzheimer’s Disease conference in December 2025, where it will present results from its Phase 2 MINDFuL trial and validation of the Early Mild Alzheimer’s Cognitive Composite.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
INmune Bio Inc. has prepared a presentation slide deck to be used in future presentations, highlighting their progress in developing immunotherapies. The company is advancing its late-stage pipeline with key programs like CORDStrom and XPro, targeting rare pediatric diseases and Alzheimer’s, respectively. They have completed Phase 2 trials for both programs and are planning regulatory filings and Phase 3 trials in the coming years. This strategic progression positions INmune Bio for regulatory acceleration and potential market entry, which could significantly impact their market presence and stakeholder interests.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
On October 23, 2025, INmune Bio Inc. announced it will host a conference call on October 30, 2025, to discuss its third-quarter financial results and provide a corporate update. This event is significant for stakeholders as it will offer insights into the company’s recent performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.